Oppenheimer & Co’s BioLineRX BLRX Stock Holding History

Oppenheimer & Co’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-39	Closed	-$10K	–	1352
2018 Q4	$10K	Sell	39 -4	-9%	-$1.93K	﹤0.01%	1231
2018 Q3	$28K	Buy	43 +26	+153%	+$14.3K	﹤0.01%	1335
2018 Q2	$9K	Buy	+17	New	+$9.03K	﹤0.01%	1321

Other funds holding BLRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Delek Group Herzliya, Israel $2.59B AUM 1.24% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Oppenheimer & Co's BLRX Position: Q1 2019 in Review

Oppenheimer & Co sold out of BioLineRX (BLRX) in Q1 2019, closing a stake of 39 shares — an estimated $10K sold.

Oppenheimer & Co first reported a position in BLRX in Q2 2018 and held it in 3 quarters. The position peaked at $28K in Q3 2018. 31 funds tracked by Wall St. Rank hold BLRX as of Q1 2019.

Oppenheimer & Co reported no remaining BioLineRX position as of Q1 2019 after selling out during the quarter.
Oppenheimer & Co sold 39 BioLineRX shares in Q1 2019, an estimated $10K.
Oppenheimer & Co first reported a position in BioLineRX in Q2 2018 and held it in 3 quarters.
Oppenheimer & Co's BioLineRX position peaked at $28K in Q3 2018.
31 funds tracked by Wall St. Rank held BioLineRX as of Q1 2019.

Based on Oppenheimer & Co's 13F filing for Q1 2019, filed 24 Apr 2019.